Ocugen, Inc.
OCGNHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeOcugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. At a $250.8M market cap, Ocugen, Inc. ranks as a micro-cap company within healthcare. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Market Cap
$250.8M
Beta
2.27
P/E (TTM)
—
P/E (Fwd)
-2.92
EPS (TTM)
$-0.26
EPS (Fwd)
$-0.25
ROE
—
ROA
-48.4%
Cash
$100.1M
Total Debt
$88.0M
Free CF
-$2.0M
52W Change
-54.0%
Annual Financials
Cash vs Debt
Where OCGN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, OCGN finished 43.57% below its 150-day moving average ($1.40) and 46.26% below its 200-day moving average ($1.47). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OCGN overbought or oversold?
At the October 20, 2026 close, OCGN's RSI(14) was 11.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $100.1M in cash comfortably exceeding the $88.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$2.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $2.5M (2022) to $4.4M (2025), reflecting a 77% increase over the period.
Ocugen, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OCGN.